A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496 · Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
PhasePhase 3
TypeInterventional
Age18 Years
WhereMesa, Arizona, United States + 121 more
SponsorTakeda
▾Tap for detailsClick for full details — eligibility, all locations, contacts
122 sitesApply